BERKELEY, Calif., July 7, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced plans to hold a conference call and webcast on July 14, 2009 at 4:30 pm Eastern time to discuss top line results from its randomized, placebo-controlled U.S. Phase 1 trial of XOMA 052 in Type 2 diabetes. Marc Y. Donath, M.D., a pioneer in anti-inflammatory approaches to Type 2 diabetes, Professor at the University Hospital of Zurich and XOMA 052 European clinical trial principal investigator, will participate on the call with XOMA management.
